Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort is a research paper published in JNCI Journal of the National Cancer Institute (2024). On theSindex it has a DataRank of 0. It has been cited 3 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Cancer Center Support
Grant: P30 CA008748
NIH
Grant: 1P50CA257881-01A1
The Memorial Sloan Kettering Cancer Center SPORE in Pancreas Cancer
NIH
Grant: NIH K12 CA184746
NCI NIH HHS
Grant: K12 CA184746
NCI NIH HHS
Grant: P50 CA257881
National Institutes of Health
AstraZeneca
Breakthrough Cancer-Conquering KRAS for Pancreatic Cancer
Memorial Sloan Kettering Cancer Center Parker Institute for Cancer Immunotherapy Pilot
Paul Calabresi Career Development Award for Clinical Oncology
Society of Memorial Sloan Kettering Cancer Center Research
Breakthrough Cancer—Conquering KRAS for Pancreatic Cancer
Parker Institute for Cancer Immunotherapy, and Break
NIH HHS
National Cancer Institute
Parker Institute for Cancer Immunotherapy, and Break
Paul Calabresi Career Development Award for Clinical Oncology
AstraZeneca
Breakthrough Cancer-Conquering KRAS for Pancreatic Cancer
NIH HHS
Memorial Sloan Kettering Cancer Center Parker Institute for Cancer Immunotherapy Pilot
Society of Memorial Sloan Kettering Cancer Center Research
FWCI
0.87
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords